|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-5-26
|
|
pubmed:abstractText |
Chemotherapy with gemcitabine and cisplatin (GC) is an active regimen in advanced transitional cell carcinoma (TCC). Traditionally, GC has been administered as a 4-week schedule. However, an alternative 3-week schedule may be more feasible. Long-term survival data for the alternative 3-week schedule and comparisons of the feasibility and toxicity between the two schedules have not previously been published.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0284-186X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
110-9
|
|
pubmed:dateRevised |
2009-5-12
|
|
pubmed:meshHeading |
pubmed-meshheading:17851853-Adult,
pubmed-meshheading:17851853-Aged,
pubmed-meshheading:17851853-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17851853-Carcinoma, Transitional Cell,
pubmed-meshheading:17851853-Cisplatin,
pubmed-meshheading:17851853-Deoxycytidine,
pubmed-meshheading:17851853-Disease Progression,
pubmed-meshheading:17851853-Drug Administration Schedule,
pubmed-meshheading:17851853-Female,
pubmed-meshheading:17851853-Humans,
pubmed-meshheading:17851853-Male,
pubmed-meshheading:17851853-Middle Aged,
pubmed-meshheading:17851853-Prognosis,
pubmed-meshheading:17851853-Retrospective Studies,
pubmed-meshheading:17851853-Treatment Outcome,
pubmed-meshheading:17851853-Urinary Bladder Neoplasms
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
|
|
pubmed:affiliation |
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. abals@as.aaa.dk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
